PageOverview.com
 

Domains targeting keyword medication administration

Keyword medication administration was used in the provided list of websites.

 
Number of websites/domains displayed: 31
Results found: 31
 

Similar searches:

 

Websites discovered:

Psoriasis Treatment – Shampoo, Spray, and Lotion – Clobex® (clobetasol propionate)
http://pageoverview.com/website-report/clobex.com
Discover Clobex® (clobetasol propionate), a powerful medication available in spray, shampoo, and lotion for the treatment of psoriasis.
  • Expected expiration: February 22nd in 2019
  • Creation date: February 22nd in 2000
  • Renew date: December 13th in 2016
  • Google Analytics: 10707947-18
Medical Reception Training | Medical Reception Course | Medical/Dental Terminology
http://pageoverview.com/website-report/wesleyhealth.com.au
Wesley is Australia's Leading Provider of Educational, Training, Medical Reception Training | Medical Reception Course and Support Services for the Medical and Dental industry - enabling students to be immediately skilled and 'Job Ready' for a career in health.
    Code - Barcode Reader Manufacturer
    http://pageoverview.com/website-report/codecorp.com
    Code designs, develops and manufactures image-based bar code readers, portable data terminals, and software tools for data collection applications. With expertise in software development, optics, imaging, and Bluetooth® wireless technology, Code has become an innovative leader in the Auto ID and Data Collection Industry.
    • Expected expiration: June 11th in 2019
    • Creation date: June 12th in 1998
    • Renew date: August 2nd in 2016
    • Google Analytics: 2202525-1
    Bion®3 - Soyez fort de l'intérieur !
    http://pageoverview.com/website-report/bion.fr
    A chaque besoin, sa solution adaptée - Découvrez comment être en forme tout au long de lannée avec la gamme Bion®3
    • Expected expiration: June 22nd in 2017
    • Creation date: November 8th in 2004
    • Renew date: June 22nd in 2016
    Kildallan N.S. - Home
    http://pageoverview.com/website-report/kildallanns.ie
    Kildallan N.S, Kildallan, Ballyconnell, Co. Cavan, homepage, history of school, junior room, middle room, senior room, history of GAA, policies, healthy eating policy, administration of medication policy, discipline policy, opening hours, school staff, Gallery, Kids Zone, Borad of Management, Parents Association, Ardlougher
      jsmi.jp
      http://pageoverview.com/website-report/jsmi.jp
      • Expected expiration: March 31st in 2018
      • Creation date: March 10th in 2003
      • Renew date: April 1st in 2017
      • Google Analytics: 8890444-1
      So you think you know Webstercare
      http://pageoverview.com/website-report/webstercare.com.au
      For more than 30 years, Webstercare® has been an innovation-led company at the vanguard of solving the problems Australians have with managing their medication.
      • Google Analytics: 47797142-1
      • Google Plus Account: 111090643490524240084
      TNKase® Acute Myocardial Infarction Treatment
      http://pageoverview.com/website-report/tnkase.com
      Learn more about single-bolus TNKase® (tenecteplase) acute myocardial infarction treatment and the 5-second TNKase® dosing and administration. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.
      • Expected expiration: March 13th in 2018
      • Creation date: March 13th in 2000
      • Renew date: October 24th in 2016
      BRILINTA® (ticagrelor) tablets | Heart Attack Treatment
      http://pageoverview.com/website-report/brilinta.com
      Read about BRILINTA® (ticagrelor) tablets, a prescription medication for heart attack treatment, or severe chest pain, also known as unstable angina.
      • Expected expiration: April 21st in 2018
      • Creation date: April 21st in 2005
      • Renew date: April 17th in 2017
      FARXIGA® (dapagliflozin) | Type 2 Diabetes Medication for Adults
      http://pageoverview.com/website-report/farxiga.com
      FARXIGA® (dapagliflozin) is an adult type 2 diabetes medication used with diet and exercise to improve glycemic control.
      • Expected expiration: August 27th in 2017
      • Creation date: August 27th in 2013
      • Renew date: August 23rd in 2016
      INGREZZA® (valbenazine) for adults with tardive dyskinesia (TD)
      http://pageoverview.com/website-report/ingrezza.com
      Learn more about INGREZZA—the first FDA-approved treatment for adults with tardive dyskinesia (TD).
      • Expected expiration: December 14th in 2018
      • Creation date: December 14th in 2015
      • Renew date: October 15th in 2017
      • Google Analytics: 76386630-3
      Acid Reflux Medication | NEXIUM® (esomeprazole magnesium)
      http://pageoverview.com/website-report/purplepill.com
      Discover NEXIUM, the Purple Pill, which offers 24-hour heartburn relief caused by acid reflux disease. Ask your doctor if NEXIUM may be right for you.
      • Expected expiration: October 29th in 2017
      • Creation date: October 29th in 1999
      • Renew date: October 25th in 2016
      Asthma research and Symbicort SMART
      http://pageoverview.com/website-report/symbicort.com
      Symbicort SMART delivered via the Symbicort Turbuhaler delivers medication to maintain asthma control and treat symptoms
      • Expected expiration: February 8th in 2018
      • Creation date: February 8th in 1999
      • Renew date: February 4th in 2017
      池袋セルフメディケーション | 処方箋無しで医薬品購入、血液検査のできる薬局
      http://pageoverview.com/website-report/self-medication.co.jp
      • Creation date: November 10th in 2016
      • Renew date: November 10th in 2016
      • Google Analytics: 103986294-1
      Cholesterol Medicine | CRESTOR® (rosuvastatin calcium)
      http://pageoverview.com/website-report/crestor.com
      Information about CRESTOR® (rosuvastatin calcium), a prescription cholesterol medicine that helps lower LDL cholesterol when diet and exercise alone are not enough.
      • Expected expiration: October 26th in 2017
      • Creation date: October 27th in 1994
      • Renew date: October 22nd in 2016
      ��Ǣ�¥ͥåȥ�� Diabetes Net. - ���襨�󥸥祤ʪ��
      http://pageoverview.com/website-report/dm-net.co.jp
      • Creation date: January 17th in 1997
      • Renew date: January 30th in 1997
      • Google Analytics: 22519342-10
      Bipolar Disorder Medication | SEROQUEL XR® (quetiapine fumarate)
      http://pageoverview.com/website-report/seroquelxr.com
      Find information to better understand major depressive disorder (MDD), bipolar disorder, bipolar depression, and SEROQUEL XR® (quetiapine fumarate).
      • Expected expiration: March 29th in 2018
      • Creation date: March 29th in 2007
      • Renew date: March 25th in 2017
      Leading EHR Software for Long Term Care & Retirement & Hospitals
      http://pageoverview.com/website-report/mede-care.com
      Leading EHR Software solutions for Long Term Care, Retirement and Hospitals. Full suite of solutions, software products, consulting, training and services.
      • Expected expiration: March 15th in 2024
      • Creation date: March 15th in 2000
      • Renew date: August 10th in 2015
      • Google Analytics: 40755935-1
      INGREZZA® (valbenazine) for adults with tardive dyskinesia (TD) | HCP Website
      http://pageoverview.com/website-report/ingrezzahcp.com
      Get information on INGREZZA safety, dosing, and efficacy to help support your adult patients with TD. See safety and product information.
      • Expected expiration: September 12th in 2019
      • Creation date: September 12th in 2017
      • Renew date: September 12th in 2017
      • Google Analytics: 76386630-4
      Poux, démangeaison, mycose, des problèmes de peau traités par Apaisyl
      http://pageoverview.com/website-report/apaisyl.com
      Poux, démangeaison, mycose, herpès labial ou autres affections cutanées sont des problèmes de peau traités par Apaisyl, gamme experte des agressions de la peau.
      • Expected expiration: July 4th in 2018
      • Creation date: July 4th in 2000
      • Renew date: June 22nd in 2017
      • Google Analytics: 15680512-1
      ���{��ÁE���N��񌤋���
      http://pageoverview.com/website-report/mhlab.jp
      日本医療・健康情報研究所は、糖尿病や生活習慣病、メタボリックシンドロームなどに関する国内外の医療、健康関連情報を収集・分析・整理し、多様なメディアを通して発信しています。
      • Expected expiration: March 31st in 2018
      • Creation date: March 14th in 2005
      • Renew date: April 1st in 2017
      IT Training | Healthcare Training | CyberTex Institute of Technology
      http://pageoverview.com/website-report/cybertex.edu
      With campuses in Austin and Killeen, CyberTex Institute of Technology provides medical, IT, and business training courses. Contact us today!
      • Google Analytics: 45345601-1
      Type 2 Diabetes Medication | BYETTA® (exenatide) injection
      http://pageoverview.com/website-report/byetta.com
      BYETTA is a non-insulin type 2 diabetes injection medication for adults.
      • Expected expiration: February 3rd in 2018
      • Creation date: February 3rd in 2004
      • Renew date: January 29th in 2017
      日本一般用医薬品連合会 - 一般用医薬品業界の連携を強化し、様々な課題について取り組みを進めます。
      http://pageoverview.com/website-report/jfsmi.jp
      日本一般用医薬品連合会のホームページです。セルフメディケーションの普及や一般用医薬品の進行及び安全対策、承認基準の見直しなど、業界を代表した提言を行い、その実現を図ります。
      • Expected expiration: February 28th in 2018
      • Creation date: February 22nd in 2012
      • Renew date: March 1st in 2017
      Vegetarian Old age Retirement homes, NRI Parents Care, Living Facility for seniors in Hyderabad
      http://pageoverview.com/website-report/heritagehealthcareindia.com
      We offer health services for senior citizens such as nursing, assisted living facility and dementia care. We have vegetarian meals, housekeeping and medication management for Hyderabad, Telangana, Andhra Pradesh.
      • Expected expiration: February 14th in 2018
      • Creation date: February 14th in 2005
      • Renew date: February 15th in 2017
      • Google Analytics: 35180983-1
      Inducing Remission in GPA & MPA Patients | Rituxan® GPA & MPA | HCP
      http://pageoverview.com/website-report/rituxanforgpampa-hcp.com
      Find information for healthcare professionals about Rituxan® (rituximab), the only FDA-approved treatment proven to induce remission in patients with GPA and MPA. INDICATION STATEMENT - Rituxan® (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Limitations of Use: Rituxan is not recommended for use in patients with severe, active infections BOXED WARNINGS and Additional Important Safety Information BOXED WARNINGS Infusion Reactions: Rituxan administration can result in serious, including fatal, infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions. Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan. Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation. Progressive Multifocal Leukoencephalopathy (PML): PML, including fatal PML, can occur in patients receiving Rituxan. Warnings and Precautions Rituxan administration can also result in additional serious, including fatal, adverse reactions including: - Tumor lysis syndrome (TLS): Administer aggressive intravenous hydration, anti‑hyperuricemic agents, monitor renal function - Infections: Withhold Rituxan and institute appropriate anti-infective therapy - Cardiac arrhythmias and angina: Discontinue infusions in case of serious or life-threatening events - Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms - Live virus vaccines: Do not administer live virus vaccines prior to or during Rituxan - Cytopenias: Monitor blood counts at regular intervals Granulomatosis With Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA or MPA patients exhibiting peripheral B-cell depletion following treatment with Rituxan. Observe patients with GPA and MPA closely for signs of infection if immunosuppressants other than corticosteroids are used concomitantly - The safety and efficacy of retreatment with Rituxan have not been established in patients with GPA and MPA - Common adverse reactions (≥15%) in the clinical study were infections, nausea, diarrhea, headache, muscle spasms, anemia, and peripheral edema. Other important adverse reactions include infusion reactions You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. For additional safety information, please see the Rituxan full prescribing information, including BOXED WARNINGS.
      • Expected expiration: November 27th in 2019
      • Creation date: November 27th in 2013
      • Renew date: December 1st in 2017
      • Google Analytics: 48974804-1
      Electronic Medical Record-EMR | Electronic Health Record Software - Optimus EMR, Inc
      http://pageoverview.com/website-report/optimusemr.com
      Optimus EMR provides industry-leading Electronic Medical Record (EMR) and Electronic Health Record (EHR) software for long term care, nursing home, skilled nursing, and post acute care facilities.
      • Expected expiration: March 14th in 2020
      • Creation date: March 14th in 2006
      • Renew date: July 11th in 2016
      • Google Analytics: 12160578-1
      Poux, démangeaison, mycose, des problèmes de peau traités par Apaisyl
      http://pageoverview.com/website-report/gammeapaisyl.com
      Poux, démangeaison, mycose, herpès labial ou autres affections cutanées sont des problèmes de peau traités par Apaisyl, gamme experte des agressions de la peau.
      • Expected expiration: June 18th in 2018
      • Creation date: June 18th in 2014
      • Renew date: November 16th in 2016
      • Google Analytics: 15680512-1
      High Blood Pressure Medication | TOPROL-XL
      http://pageoverview.com/website-report/azhypertensionbrands.com
      • Expected expiration: November 19th in 2018
      • Creation date: November 19th in 2013
      • Renew date: November 19th in 2013
      100% Safe & Secure | Pharmacy Online 365
      http://pageoverview.com/website-report/pharmacyonline365.co
      Order your medication online 24 hours a day 365 days a year. Give us a call today on US toll free: 1-888-474-8078
      • Expected expiration: January 22nd in 2019
      • Creation date: January 23rd in 2017
      • Renew date: January 28th in 2018
      Asthma Treatment | PULMICORT FLEXHALER® (budesonide inhalation powder, 90 mcg & 180 mcg)
      http://pageoverview.com/website-report/pulmicortflexhaler.com
      Official patient site. Learn about PULMICORT FLEXHALER a medication for the maintenance treatment of asthma symptoms in adults and children 6 years or older. Find information about the inhaler and side effects and a How to Use FLEXHALER video.
      • Expected expiration: November 16th in 2017
      • Creation date: November 16th in 2006
      • Renew date: November 12th in 2016
      0.0311 // 2024-05-04 21:38:51
      All Rights reserved 2018 © PageOverview.com